Hormonal
Unimolecular GLP-1/Apelin hybrid peptides (specifically ELA, ELA-Lys12, and ELA-Lys38) cause prominent appetite suppression in mice without inducing malaise, with effects lasting up to 42 hours for the base peptide and 63 hours for acylated forms.
This research suggests that combining GLP-1 and Apelin pathways in a single peptide molecule can effectively reduce food intake for extended periods (up to 63 hours with acylation) without causing the nausea often seen with current GLP-1 drugs. While promising in mice, this is pre-clinical data and not yet a human treatment option.
Assessment of effects on feeding behaviour revealed substantial reductions of food intake by ELA, durable for 42 h. Peptide acylation extended the duration of appetite suppressive actions to 63 h. Studies in rats suggested that ELA-induced inhibition of food intake was not linked to malaise.
Why this rating
The study is conducted in mice and rats, not humans, limiting direct applicability to human clinical outcomes.
Source
Unimolecular <scp>GLP</scp> ‐1/Apelin Hybrid Peptides Cause Prominent Appetite Suppression, as Well as Enhancing Insulin Secretion, Beta‐Cell Survival and Glycaemic Regulation
Ananyaa Sridhar et al. · Diabetes Obesity and Metabolism · 2026
DOI 10.1111/dom.70647
More from this paper
- GLP-1/Apelin hybrid peptides (ELA, ELA-Lys12, ELA-Lys38) significantly improve glucose tolerance and insulin secretion in both lean and high-fat-fed mice, with effects lasting up to 21 hours for acylated forms.Moderate
- GLP-1/Apelin hybrid peptides enhance beta-cell proliferation and protect against cytokine-induced apoptosis, contributing to beta-cell survival.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →